行情

BMY

BMY

百时美施贵宝
NYSE

实时行情|Nasdaq Last Sale

60.94
+0.51
+0.84%
交易中 10:18 03/08 EST
开盘
60.55
昨收
60.43
最高
60.94
最低
60.13
成交量
180.83万
成交额
--
52周最高
67.16
52周最低
45.76
市值
1,365.35亿
市盈率(TTM)
-15.1751
分时
5日
1月
3月
1年
5年
国产PD-1抗癌药的好日子到头了?
虎嗅APP · 8小时前
布里斯托尔·迈尔斯·斯奎布(Bristol Myers Squibb Co.)股价周五上涨,但跑输大盘
Shares of Bristol Myers Squibb Co. rose 1.84% to $60.43 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...
marketwatch.com · 2天前
肝纤维化药物市场的全面回顾将在-2026年期间录得健康的CAGR
Mar 05, 2021 (Market Insight Reports) -- Selbyville, Delaware, According to this latest study, the 2020 growth of Liver Fibrosis Drug will have significant...
Market Insight Reports · 2天前
万事达卡,NVIDIA和Costco的主要股票报告
Zacks.com · 2天前
2020年至2027年全球多形性胶质母细胞瘤(GBM)治疗市场的全球趋势,市场份额,行业规模,增长,机会和市场预测
Mar 05, 2021 (Market Insight Reports) -- The report for Recurrent Glioblastoma Multiforme (GBM) Treatment offers an assiduous analysis of contemporary market...
Market Insight Reports · 3天前
到2027年顶级公司,驱动因素,现有趋势和全球预测的小分子API市场分析| IDC中国约翰逊·马修(Johnson Matthey),齐格弗里德控股公司(Siegfried Holding AG),辉瑞公司,赛诺菲(Sanofi)SA,诺华公司| FMI报告与专家审阅
Mar 05, 2021 (MARKITWIRED via COMTEX) -- A study published by FMI - Small Molecule API Market: Global Industry Analysis and Opportunity Assessment, 2017-2027...
Markitwired · 3天前
TMJ植入物市场2020:主要参与者的预期发展,份额,需求和研究-KDMI的研究预测和预测2025
Mar 05, 2021 (Market Insight Reports) -- The research report on the global TMJ Implants Market published by Fast Mr demonstrates the crucial aspects that are...
Market Insight Reports · 3天前
2020顶级药企美国区营收,均超33%
界面新闻 · 3天前
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解BMY最新的财务预测,通过BMY每股收益,每股净资产,每股现金流等数据分析百时美施贵宝近期的经营情况,然后做出明智的投资选择。
分析师评级

19位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测BMY价格均价为75.53,最高价位86.00,最低价为66.00。
EPS
机构持股
总机构数: 2,976
机构持股: 17.35亿
持股比例: 77.45%
总股本: 22.40亿
类型机构数股数
增持
922
7,549.35万
建仓
348
696.04万
减持
852
9,097.44万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
+0.63%
制药与医学研究
+0.56%
高管信息
Chairman/Chief Executive Officer/Director
Giovanni Caforio
Chief Financial Officer/Executive Vice President
David Elkins
Chief Human Resource Officer/Senior Vice President
Ann Judge
Chief Human Resource Officer/Senior Vice President
Ann Powell
Executive Vice President/General Counsel
Sandra Leung
Executive Vice President/Director of Investor Relations
John Elicker
Executive Vice President
Nadim Ahmed
Executive Vice President
Christopher Boerner
Executive Vice President
Samit Hirawat
Executive Vice President
Kathryn Metcalfe
Executive Vice President
Elizabeth Mily
Executive Vice President
Louis Schmukler
Executive Vice President
Rupert Vessey
Senior Vice President/Chief Information Officer
Paul von Autenried
Senior Vice President/Chief Compliance Officer
Adam Dubow
Senior Vice President/Controller
Karen Santiago
Senior Vice President
Joseph Eid
Vice President/Director of Investor Relations/IR Contact Officer
Tim Power
Lead Director/Independent Director
Vicki Sato
Lead Director/Independent Director
vicki Sato
Independent Director
Peter Arduini
Independent Director
Robert Bertolini
Independent Director
Michael Bonney
Independent Director
Matthew Emmens
Independent Director
Julia Haller
Independent Director
Dinesh Paliwal
Independent Director
Paula Price
Independent Director
Derica Rice
Independent Director
Theodore Samuels
Independent Director
Gerald Storch
Independent Director
Karen Vousden
Independent Director
Phyllis Yale
公告日期
每股分红
除权日期
2021/03/01
每股分红:USD 0.49
2021/03/31
2020/12/10
每股分红:USD 0.49
2020/12/31
2020/09/10
每股分红:USD 0.45
2020/10/01
2020/06/11
每股分红:USD 0.45
2020/07/02
2020/03/02
每股分红:USD 0.45
2020/04/02
2019/12/05
每股分红:USD 0.45
2020/01/02
2019/09/11
每股分红:USD 0.41
2019/10/03
2019/06/13
每股分红:USD 0.41
2019/07/03
2019/03/07
每股分红:USD 0.41
2019/04/04
2018/12/06
每股分红:USD 0.41
2019/01/03
2018/09/12
每股分红:USD 0.4
2018/10/04
2018/06/14
每股分红:USD 0.4
2018/07/05
2018/03/01
每股分红:USD 0.4
2018/04/05
2017/12/07
每股分红:USD 0.4
2018/01/04
2017/09/13
每股分红:USD 0.39
2017/10/05
2017/06/14
每股分红:USD 0.39
2017/07/05
2017/03/03
每股分红:USD 0.39
2017/04/05
2016/12/09
每股分红:USD 0.39
2017/01/04
2016/08/04
每股分红:USD 0.38
2016/10/05
2016/06/13
每股分红:USD 0.38
2016/06/29
2016/03/04
每股分红:USD 0.38
2016/03/30
2015/12/10
每股分红:USD 0.38
2015/12/30
2015/09/18
每股分红:USD 0.37
2015/09/30
2015/06/19
每股分红:USD 0.37
2015/07/01
2015/03/05
每股分红:USD 0.37
2015/04/01
2014/12/10
每股分红:USD 0.37
2014/12/30
2014/09/17
每股分红:USD 0.36
2014/10/01
2014/06/18
每股分红:USD 0.36
2014/07/01
2014/03/04
每股分红:USD 0.36
2014/04/02
2013/12/19
每股分红:USD 0.36
2013/12/31
2013/09/18
每股分红:USD 0.35
2013/10/02
2013/06/20
每股分红:USD 0.35
2013/07/02
BMY 简况
Bristol-Myers Squibb Co从事生物医药产品的探索、研发、授权、制造、推广、分销及销售业务。该公司的医药产品包括化学合成药物、小分子药物和经生物加工制成的生物制剂。小分子药物为口服药丸或药片。生物制剂为注射产品或输液产品。该公司的产品包括Empliciti、Opdivo、Sprycel、Yervoy、Eliquis、Orencia、Baraclude、Hepatitis C Franchise、Reyataz Franchise和Sustiva Franchise。该公司提供不同类型的治疗用药,用于治疗人类免疫缺陷病毒(HIV)感染等病毒性疾病、肿瘤、免疫系统病和心血管疾病。其产品销往世界各地的批发商、零售药房、医院、政府机构和医学界。该公司的子公司是Celgene Corp和MyoKardia,Inc。

微牛提供Bristol-Myers Squibb Co(NYSE-BMY)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的BMY股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易BMY股票基本功能。